🇺🇸 FDA

Intelligence · Clinical Pipeline

Neurology & CNS · Phase II

Neurology & CNS programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
230

Quick answer

Neurology & CNS Phase II programs: NovaPharmaNews indexes 230 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 4 of 5

  1. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  2. Placebo RO7269162, RO7269162, RO7269162, RO7269162, FLORBETABEN (18F), FLUTEMETAMOL (18F)

    Hoffmann-La Roche

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  3. Placebo for ML-007C-MA bilayer tablet

    MapLight Therapeutics

    Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

    phase 2 small molecule active

    1 trial

  4. Placebo of Dexamfetamine sulfate 20 mg modified-release capsule, Dexamfetamine sulfate 20 mg modified-release capsule, Attentin 5 mg, Tablette, Dexamfetamine sulfate 15 mg modified-release capsule, Dexamfetamine sulfate 10 mg modified-release capsule, Placebo of Attentin 5 mg 10 mg tablets, Placebo of Dexamfetamine sulfate 15 mg modified-release capsule, Attentin 10 mg Tablette, Placebo of Dexamfetamine sulfate 10 mg modified-release capsule

    Lacuna Pharma Pty Ltd

    Adults with ADHD and moderate to severe depression

    phase 2 small molecule active

    1 trial

  5. Placebo sterile solution for SC injection, Obexelimab

    Zenas BioPharma

    RELAPSING MULTIPLE SCLEROSIS

    phase 2 small molecule active

    1 trial

  6. Placebo to MK-1167, MK-1167, MK-1167, MK-1167

    Merck Sharp and Dohme

    Alzheimer’s disease dementia

    phase 2 small molecule active

    1 trial

  7. Placebo to match ACP-204

    Lacuna Pharma Pty Ltd

    Alzheimer Disease psychosis

    phase 2 small molecule active

    1 trial

  8. PrimeC

    NeuroSense Therapeutics

    Alzheimer Disease

    phase 2 small molecule terminated

    1 trial

  9. Proleukin

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  10. Psilocybin

    COGNITION THERAPEUTICS INC

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  11. Psilocybin 25 mg Capsules, TRITTICO 60 mg/ml gocce orali, soluzione, PCB2 (Placebo of psilocybin 25mg), Trazodone placebo (pharmaceutical master preparation prepared according to the Good Pharmacy Practice)

    Pari Pharma GmbH

    Treatment-resistant depression

    phase 2 small molecule active

    1 trial

  12. Psilocybin capsules 15 mg, Psilocybin capsules 25 mg, Psilocybin capsules 1 mg

    Disc Medicine

    Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).

    phase 2 small molecule active

    1 trial

  13. RAP-219

    Rapport Therapeutics

    Focal Epilepsy

    phase 2 small molecule active

    1 trial

  14. RHB-104

    RedHill Biopharma

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  15. RO7046015, RO7046015

    Hoffmann-La Roche

    Early Idiopathic Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

  16. RO7268489, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, RO7268489 Placebo, RO7268489, RO7268489, RO7268489

    Hoffmann-La Roche

    Progressive Forms of Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  17. ROT-TDS, Neupro 8 mg/24 h transdermal patch, Neupro 8 mg/24 h transdermal patch

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  18. RP5063

    REVIVA PHARMACEUTICALS HOLDINGS, INC.

    Acute Schizophrenia

    phase 2 small molecule completed

    1 trial

  19. Radotinib HCl, Placebo for Radotinib HCl

    Alphapharm Pty Ltd

    Treatment of Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

  20. Rimonabant

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  21. Risperidone

    Indivior Pty Ltd

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  22. Rozlytrek, Rozlytrek, Rozlytrek

    Hoffmann-La Roche

    Pediatric Solid tumors and primary central nervous system (CNS) tumors

    phase 2 small molecule active

    1 trial

  23. S1RA plus NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial

  24. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 2 small molecule completed

    1 trial

  25. SAGE-547

    SUPERNUS PHARMACEUTICALS, INC.

    Severe Postpartum Depression

    phase 2 small molecule completed

    1 trial

  26. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  27. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  28. SAGE-718-matching placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  29. SALINE, OTHER PLASMA PROTEIN FRACTIONS , Octaplasma 45-70 mg/ml pulver og væske til infusjonsvæske, oppløsning, Saline (NaCl)

    Wuhan Createrna Science and Technology Co., Ltd

    Early symptomatic phase Alzheimer's disease

    phase 2 small molecule active

    1 trial

  30. SK-PC-B70M

    Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  31. SNUBH-NM-333(18F)

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 other terminated

    1 trial

  32. SPD489 (lisdexamfetamine dimesylate)

    Takeda

    Schizophrenia and Predominant Negative Symptoms

    phase 2 small molecule completed

    1 trial

  33. SPM 962

    Otsuka Beijing Research Institute

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  34. SPN-817

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  35. SUL-238, Identical to test product except without active substance

    Sana Biotechnology

    Parkinson’s Disease

    phase 2 small molecule active

    1 trial

  36. SYNTOCINON 40 i.e./ml pršilo za nos, raztopina, Oxytocin Placebo

    The George Institute

    schizophrenia or other primary psychotic disorders (SSD)

    phase 2 small molecule active

    1 trial

  37. Sarcosine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenias

    phase 2 small molecule completed

    1 trial

  38. Sarcosine and D-serine

    Hospital Authority, Hong Kong

    Schizophrenias

    phase 2 small molecule completed

    1 trial

  39. Sodium Oxybate

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  40. Solriamfetol

    Axsome Therapeutics

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  41. Soticlestat

    Takeda

    Epilepsy

    phase 2 small molecule terminated

    1 trial

  42. TAK-041

    NEUROCRINE BIOSCIENCES INC

    Stable Schizophrenia

    phase 2 small molecule completed

    1 trial

  43. TAK-063 20 mg

    Takeda

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  44. TAK-071

    Takeda

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  45. TAK-653

    Takeda

    Treatment-Resistant Depression

    phase 2 small molecule terminated

    1 trial

  46. TAK-935

    Takeda

    Epilepsy

    phase 2 small molecule completed

    2 trials

  47. TNX-601 ER

    Tonix Pharmaceuticals Holding

    Depression

    phase 2 small molecule completed

    1 trial

  48. TOCILIZUMAB, FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE

    Novartis Pharmaceuticals

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many neurology & cns Phase II programs exist?

230 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.